EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
about
Advances in rheumatology: new targeted therapeuticsSubcutaneous or intramuscular methotrexate for rheumatoid arthritisFish oil supplements for rheumatoid arthritisMethotrexate for ankylosing spondylitisFolic Acid Supplementation for Rheumatoid Arthritis Patients on Methotrexate: The Good Gets BetterInterventions for periodontal disease in people with rheumatoid arthritisMethotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysisEtanercept for the treatment of rheumatoid arthritisPain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondyloarthritis) and gastrointestinal or liver comorbidityPain management for inflammatory arthritis and gastrointestinal or liver comorbidityCombination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)Combination therapy for pain management in inflammatory arthritis2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisAdding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implicationsRheumatoid Arthritis: The Stride from Research to Clinical PracticeThe specialist physician's approach to rheumatoid arthritis in South AfricaMethotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of AdministrationAnimal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive ReviewManagement of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary FibrosisHepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendationsIncidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysisAccess to an optimal treatment. Current situationPrevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateEstablishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare WorkshopOutcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature reviewAdvances in the treatment of polyarticular juvenile idiopathic arthritisBiologic agents for rheumatoid arthritis--negotiating the NICE technology appraisalsTumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literatureUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Personalized medicine in rheumatology2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiativeLeukoencephalopathy due to oral methotrexateThe new 2012 German recommendations for treating rheumatoid arthritis : differences compared to the European standpointCost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in chinaEffect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trialsSTAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis
P2860
Q21093257-07A21155-5A81-44CD-8C9F-C0496A030FD2Q24187565-78A98989-6931-40B5-BB9F-FBDDCABD8D61Q24197686-C13FE3E4-3398-4698-8375-30C1D0136B4DQ24200564-09E5AF26-90EE-4193-841E-093ABA714D6CQ24200922-60238376-644A-43B5-94FE-A2F219B4CBB2Q24200961-FB011DDA-7577-4DF8-9FE4-4097AA333F34Q24202055-7DF16BF8-8DC0-465E-BC03-BC36956F6B41Q24202751-4929E30E-1695-4CE8-9C56-B78A1C9C5D42Q24203871-EDA45460-6042-400B-91DB-AC0E08857A8AQ24235302-5BAB8290-EB23-4347-9302-087577634EA5Q24235846-AFDA49E5-F51B-4936-852C-694406CF9D44Q24236350-2B81C385-1C2F-4A1A-A936-81865614236CQ24603648-998C6DF8-F0FB-48E7-B228-FF18E305632BQ24631295-27956050-AAF2-459A-A36A-3DEA34917FDDQ26738960-199B7E63-0735-49D9-9E98-F316CAC80EBCQ26747512-A5775872-B1AC-4FBC-810D-94B6871322F8Q26765122-01EBCC43-E0B8-47C2-9E2A-B012D389FD6FQ26769021-373B0903-7C33-43B6-AFD6-67C0CD6DA80DQ26774874-64E696B0-5A71-4C9F-BCC7-9D36675FC256Q26781712-79DC3096-1674-4653-968D-6F248E65A7EBQ26784247-F83AAB4C-D54B-4ED0-B6EE-D76EC223237FQ26799036-86142D8B-433C-490D-9E9A-5507B373B798Q26799304-F80F07AB-4D67-462C-B8D4-31258CC4D1E2Q26824859-3E34F96D-016F-48A2-8168-047A5C2039A3Q26828418-E9B7C94E-02FF-4B2C-85A4-E7DE74C82AA7Q26852235-04636D94-74B5-44E9-9AEE-C0E72F95E0BAQ26859134-5076CE6A-C340-4C90-A644-320B79CA2FFBQ26859493-B9C46092-46E8-456C-B440-FE785C9CBCBAQ26995202-2C55CB8D-17B9-4108-A22B-C3A92577B465Q27001017-D8630B6B-DAB4-4883-9BBB-FFDA615A3410Q27010957-22DEBFB1-DC69-4849-8D6D-E238EAF8EFB7Q27012134-DFA7D6FC-D179-4783-B158-08B2533A7306Q27691388-C2BEEB0F-0DF1-4167-ACAC-EFD1777CE8A2Q28077413-6D26F4EE-6BE9-4BFD-A663-E51387A3B8FAQ28081356-0B361A4D-C07E-48E5-8E1D-400D38E64D7EQ28299271-B198317C-C405-428C-8240-3E7059266915Q28468689-94A1624B-543F-4182-B291-D2C5E204FDB3Q28484306-04E23AD5-AF01-4FCA-9DCC-579D57826918Q28543128-BB4910A8-8FC4-4CD2-8694-9E64951C329CQ28554987-8B9C5389-F574-48C6-8044-2EE5D21D2871
P2860
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
EULAR recommendations for the ...... -modifying antirheumatic drugs
@ast
EULAR recommendations for the ...... -modifying antirheumatic drugs
@en
EULAR recommendations for the ...... -modifying antirheumatic drugs
@en-gb
EULAR recommendations for the ...... -modifying antirheumatic drugs
@nl
type
label
EULAR recommendations for the ...... -modifying antirheumatic drugs
@ast
EULAR recommendations for the ...... -modifying antirheumatic drugs
@en
EULAR recommendations for the ...... -modifying antirheumatic drugs
@en-gb
EULAR recommendations for the ...... -modifying antirheumatic drugs
@nl
prefLabel
EULAR recommendations for the ...... -modifying antirheumatic drugs
@ast
EULAR recommendations for the ...... -modifying antirheumatic drugs
@en
EULAR recommendations for the ...... -modifying antirheumatic drugs
@en-gb
EULAR recommendations for the ...... -modifying antirheumatic drugs
@nl
P2093
P2860
P50
P356
P1476
EULAR recommendations for the ...... -modifying antirheumatic drugs
@en
P2093
Angela Zink
Bernard Combe
Cecile Gaujoux-Viala
Daniel Aletaha
David L Scott
Ferdinand C Breedveld
Gerd Burmester
Jackie Nam
Johannes W J W Bijlsma
P2860
P304
P356
10.1136/ARD.2009.126532
P407
P50
P5008
P577
2010-05-05T00:00:00Z
2010-06-01T00:00:00Z
P5875
P6179
1039712973